The US Food and Drug Administration (FDA) has approved Merck’s Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia, with cholesterol-lowering medication simvastatin.
The approval is based upon clinical bioequivalence studies in healthy subjects, which demonstrated that the administration of Juvisync is equivalent to the co-administration of corresponding doses of the two individual medications as separate tablets.
Juvisync will enable healthcare providers to help patients who need the blood sugar-lowering benefits of a dipeptidyl peptidase-4 inhibitor and the cholesterol-lowering benefits of simvastatin with the convenience of a single tablet once daily.
However, the therapy should be discontinued immediately if markedly elevated creatine phosphokinase levels occur or myopathy is diagnosed or suspected, the company said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData